Sickle Cell Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer

The Key Sickle Cell Disease Companies in the market include - Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others.

DelveInsight's "Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom.

To Know in detail about the Sickle Cell Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sickle Cell Disease Market Forecast [https://www.delveinsight.com/sample-request/sickle-cell-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Sickle Cell Disease Market Report:

*
Amon the 6MM countries the Sickle Cell Disease market size was valued ~USD 650 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In November 2024, BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial-stage biopharmaceutical company focused on transformative therapies for oncology and rare diseases, announced that initial results from a Phase 1 clinical trial of motixafortide-evaluated both as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization in gene therapies for sickle cell disease (SCD)-will be presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, scheduled for December 7-10, 2024, in San Diego, California. Conducted in collaboration with Washington University School of Medicine in St. Louis, the proof-of-concept study aims to explore innovative HSC mobilization strategies that could enhance the treatment experience for SCD patients pursuing gene therapy.

*
In June 2024, Vertex Pharmaceuticals has shared long-term results for its gene therapy, Casgevy (exa-cel), in patients with sickle cell disease or transfusion-dependent beta-thalassemia (TDT).

*
In 2023, the United States held the largest market share for Sickle Cell Disease among the 6MM, with approximately USD 603 million, followed by France and the UK.

*
In May 2023, The experimental cell-based gene-editing therapy called EDIT-301, administered as a single infusion, received orphan drug designation from the US Food and Drug Administration (FDA) for treating sickle cell disease (SCD).

*
At present, treatments for Sickle Cell Disease include NSAIDs, blood transfusions, chelating agents, nutritional supplements, and broad-spectrum antibiotics. Additionally, the US FDA has approved several therapies for this condition, such as DROXIA (hydroxyurea), ENDARI (L-glutamine oral powder), ADAKVEO (crizanlizumab-tmca), and OXBRYTA (voxelotor).

*
In 2023, the United States had the largest total number of prevalent Sickle Cell Disease cases among the 6MM.

*
In the US, Sickle Cell Anemia (hemoglobin S/S or hemoglobin S/0-thalassemia) was the most common subtype of Sickle Cell Disease among the type-specific prevalent cases in 2023.

*
In the EU4 and the UK, France had the highest prevalence of Sickle Cell Disease cases, followed by the UK, while Spain reported the lowest number of cases.

*
Key Sickle Cell Disease Companies: Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others

*
Key Sickle Cell Disease Therapies: CASGEVY (exagamglogene autotemcel), Inclacumab, GMI-1687, BIVV003, CSL889, Siplizumab, Etavopivat Tablets, VIT-2763, Crizanlizumab, Epeleuton, Voxelotor, Hydroxycarbamide, Exagamglogene autotemcel, Mitapivat, Canakinumab, ALXN1820, Crovalimab, EDIT 301, BIVV003, BEAM101, Hemopexin, and others

*
The Sickle Cell Disease epidemiology based on gender analyzed that Sickle Cell Disease affects males and females equally

*
The Sickle Cell Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sickle Cell Disease pipeline products will significantly revolutionize the Sickle Cell Disease market dynamics.

Sickle Cell Disease Overview

Sickle cell disease (SCD) comprises inherited red blood cell disorders resulting from an abnormality in the structure of hemoglobin known as sickle hemoglobin (HbS), which encodes the beta hemoglobin subunit.

Get a Free sample for the Sickle Cell Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/sickle-cell-disease-market [https://www.delveinsight.com/report-store/sickle-cell-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Sickle Cell Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Sickle Cell Disease Epidemiology Segmentation:

The Sickle Cell Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Sickle Cell Disease

*
Prevalent Cases of Sickle Cell Disease by severity

*
Gender-specific Prevalence of Sickle Cell Disease

*
Diagnosed Cases of Episodic and Chronic Sickle Cell Disease

Download the report to understand which factors are driving Sickle Cell Disease epidemiology trends @ Sickle Cell Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/sickle-cell-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Sickle Cell Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sickle Cell Disease market or expected to get launched during the study period. The analysis covers Sickle Cell Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sickle Cell Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sickle Cell Disease Therapies and Key Companies

*
CASGEVY (exagamglogene autotemcel): Vertex Pharmaceuticals/CRISPR Therapeutics

*
ENDARI (L-glutamine): Emmaus Life Sciences

*
Mitapivat: Agios Pharmaceuticals

*
Inclacumab: Pfizer

*
GMI-1687: Glycomimetics

*
BIVV003: Sanofi

*
CSL889: CSL Behring

*
Siplizumab: ITB-Med LLC

*
Etavopivat Tablets: Novo Nordisk A/S

*
VIT-2763: Fortrea, Inc.

*
Crizanlizumab: Novartis

*
Epeleuton: Afimmune

*
Voxelotor: Pfizer

*
Hydroxycarbamide: ADDMEDICA SASA

*
Exagamglogene autotemcel: CRISPR Therapeutics/Vertex Pharmaceuticals

*
Mitapivat: Agios Pharmaceuticals

*
Canakinumab: Novartis

*
ALXN1820: Alexion Pharmaceuticals

*
Crovalimab: Chugai Pharmaceutical/Roche

*
EDIT 301: Editas Medicine

*
BIVV003: Sangamo Therapeutics

*
BEAM101: Beam Therapeutics

*
Hemopexin: CSL Behring

Discover more about therapies set to grab major Sickle Cell Disease market share @ Sickle Cell Disease Treatment Landscape [https://www.delveinsight.com/sample-request/sickle-cell-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Sickle Cell Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom)]

*
Key Sickle Cell Disease Companies: Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others

*
Key Sickle Cell Disease Therapies: CASGEVY (exagamglogene autotemcel), Inclacumab, GMI-1687, BIVV003, CSL889, Siplizumab, Etavopivat Tablets, VIT-2763, Crizanlizumab, Epeleuton, Voxelotor, Hydroxycarbamide, Exagamglogene autotemcel, Mitapivat, Canakinumab, ALXN1820, Crovalimab, EDIT 301, BIVV003, BEAM101, Hemopexin, and others

*
Sickle Cell Disease Therapeutic Assessment: Sickle Cell Disease current marketed and Sickle Cell Disease emerging therapies

*
Sickle Cell Disease Market Dynamics: Sickle Cell Disease market drivers and Sickle Cell Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Sickle Cell Disease Unmet Needs, KOL's views, Analyst's views, Sickle Cell Disease Market Access and Reimbursement

To know more about Sickle Cell Disease companies working in the treatment market, visit @ Sickle Cell Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/sickle-cell-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Sickle Cell Disease Market Report Introduction

2. Executive Summary for Sickle Cell Disease

3. SWOT analysis of Sickle Cell Disease

4. Sickle Cell Disease Patient Share (%) Overview at a Glance

5. Sickle Cell Disease Market Overview at a Glance

6. Sickle Cell Disease Disease Background and Overview

7. Sickle Cell Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Sickle Cell Disease

9. Sickle Cell Disease Current Treatment and Medical Practices

10. Sickle Cell Disease Unmet Needs

11. Sickle Cell Disease Emerging Therapies

12. Sickle Cell Disease Market Outlook

13. Country-Wise Sickle Cell Disease Market Analysis (2020-2034)

14. Sickle Cell Disease Market Access and Reimbursement of Therapies

15. Sickle Cell Disease Market Drivers

16. Sickle Cell Disease Market Barriers

17. Sickle Cell Disease Appendix

18. Sickle Cell Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sickle-cell-disease-market-to-show-remarkable-growth-trends-from-2024-to-2034-delveinsight-reports-sanofi-csl-behring-itbmed-llc-novo-nordisk-as-fortrea-inc-novartis-afimmune-pfizer]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/blog/



This release was published on openPR.